TS expression, assessed by H-score, demonstrated positive outcomes for pemetrexed use in NSCLC with low-TS versus high-TS levels resulting in PFS 4.8 versus 3.4 months (P = 0.01). Here, TYMS is linked to non-small cell lung carcinoma.